2 1 Shi Ji Jing Ji Bao Dao·2026-01-20 08:55Core Viewpoint - Zhaoyan New Drug has released its annual performance forecast, expecting a significant increase in net profit for 2025, driven by rising market prices of biological assets and stable laboratory operations [1] Group 1: Financial Performance - The company anticipates a net profit attributable to shareholders of approximately 232.61 million to 348.92 million yuan for 2025, representing a year-on-year increase of 214.00% to 371.00% [1] - The expected net profit after deducting non-recurring gains and losses is projected to be around 246.38 million to 369.57 million yuan, with a year-on-year growth of 945.20% to 1,467.70% [1] Group 2: Contributing Factors - The increase in fair value of biological assets is attributed to both rising market prices and natural growth, positively impacting the company's performance [1] - Despite maintaining stable operations in the laboratory, the company experienced a decline in revenue and gross margin from performance contracts due to previous intense industry competition, leading to a decrease in profit contribution from laboratory services [1]